title: Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.
authors.forename: A
authors.initials: A
authors.lastname: Shimoni
authors.forename: M
authors.initials: M
authors.lastname: Leiba
authors.forename: M
authors.initials: M
authors.lastname: Schleuning
authors.forename: G
authors.initials: G
authors.lastname: Martineau
authors.forename: M
authors.initials: M
authors.lastname: Renaud
authors.forename: M
authors.initials: M
authors.lastname: Koren-Michowitz
authors.forename: E
authors.initials: E
authors.lastname: Ribakovski
authors.forename: P
authors.initials: P
authors.lastname: le Coutre
authors.forename: R
authors.initials: R
authors.lastname: Arnold
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: A
authors.initials: A
authors.lastname: Nagler
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069439:Dasatinib; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016019:Survival Analysis; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; C498826:nilotinib; D000069439:Dasatinib